查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1824014

TCR-T 療法市場報告：至2031年的趨勢、預測與競爭分析

TCR-T Therapy Market Report: Trends, Forecast and Competitive Analysis to 2031
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2025年至2031年，全球TCR-T療法市場將以12.1%的年複合成長率成長，難治性/復發性黑色素瘤、滑膜肉瘤、多發性骨髓瘤和肺癌等市場將迎來發展機會。該市場的主要驅動力是免疫腫瘤學資金的增加以及基因工程技術的不斷進步。

  • 根據Lucintel的預測，自體腫瘤預計在預測期內將出現高速成長。
  • 從應用來看，難治性和復發性黑色素瘤預計將出現最高的成長。
  • 依地區分類，預計亞太地區將在預測期內實現最高成長。

TCR-T療法市場的新趨勢

TCR-T 療法市場正隨著新趨勢的出現而不斷演變，這些趨勢重塑癌症治療格局。這些趨勢主要由技術進步、個人化醫療以及免疫治療方法研究的活性化推動。以下是改變 TCR-T 療法市場的五個關鍵趨勢：

  • 個人化癌症治療：TCR-T 療法正朝著更個人化的方向發展，利用每位患者獨特的癌症特徵來開發標靶治療。這一趨勢包括分離患者癌細胞特有的腫瘤抗原，並開發靶向這些抗原的T 細胞。隨著 TCR-T 療法變得更加精準，治療效果將更加顯著，副作用將最小化，治療成功率也會提高。
  • 固體癌研究日益受到關注：雖然TCR-T療法傳統上在治療血液系統癌症方面更為成功，但研究人員也越來越關注固體癌。固體癌因其複雜的微環境和難以有效靶向抗原而面臨更大的挑戰。然而，TCR-T技術的持續創新使得肺癌、乳癌和大腸直腸癌等固體癌的標靶治療成為可能，大幅拓展了TCR-T療法在癌症治療中的潛在應用。
  • 全球臨床試驗的擴張：臨床試驗的擴張是TCR-T療法市場的另一個主要趨勢。隨著生技公司、學術機構和監管機構之間合作的加強，臨床試驗的數量和範圍都在不斷擴大，尤其是在中國和印度等新興市場。臨床試驗對於證明TCR-T療法的安全性和有效性非常重要，隨著臨床試驗的增多，核准和廣泛應用的途徑也變得更加清晰。
  • TCR-T 療法與其他免疫療法的整合：TCR-T 療法正擴大與其他免疫療法（包括 CAR-T 療法、免疫查核點抑制劑和癌症疫苗）聯合應用。其目標是同時靶向多種途徑，以增強整體治療效果。結合不同的免疫療法可以更有效地活化免疫系統對抗癌症，這可能為患者帶來更持久、更長期的益處。
  • 生產和可擴展性的進步：TCR-T 療法面臨的關鍵挑戰之一是個人化 T 細胞的生產過程複雜且成本高昂。然而，T 細胞生產的可擴展性取得進展，包括利用自動化和人工智慧來簡化流程。這些進步有望降低生產成本，並使 TCR-T 療法更廣泛地普及，惠及更廣泛的患者群體。

TCR-T 療法市場被個人化治療、關注固體癌、全球臨床試驗、聯合治療和製造業進步等趨勢再形成，這些趨勢有望提高 TCR-T 療法的可及性、有效性和可負擔性，推動其進入主流癌症治療領域。

TCR-T療法市場的最新趨勢

受研究、臨床試驗和監管核准的推動，TCR-T 療法市場快速成長。近期，TCR-T 療法的療效和可近性取得了顯著進展。以下五項關鍵進展塑造了 TCR-T 療法市場的現狀。

  • FDA核准TCR-T 療法：美國食品藥物管理局（FDA）近期核准了數種用於治療血癌（包括黑色素瘤和白血病）的TCR-T 療法。這些核准標誌著 TCR-T 療法商業化邁出的重要一步，並為患者提供了獲得尖端治療的途徑。 FDA 對 TCR-T 療法的核准流程加快，尤其是在危及生命的癌症領域，反映出人們對該技術潛力的日益核准。
  • 固體癌治療的突破：TCR-T療法在固體癌治療的應用已取得重大進展。從歷史上看，TCR-T療法對血液系統癌症更有效，但新的策略出現，以克服固體癌帶來的挑戰。針對肺癌、大腸直腸癌和胰腺癌的臨床試驗已顯示出良好的療效，這可能顯著拓展TCR-T療法的市場，並使其成為更廣泛患者的治療選擇。
  • TCR-T 療法開發的國際合作：在 TCR-T 療法的開發中，國際夥伴關係正變得越來越普遍。生物技術公司、學術機構和醫療保健提供者之間的合作有助於簡化臨床試驗流程並共用知識和資源。此類夥伴關係也有助於降低 TCR-T 療法的開發成本，使其更經濟實惠且易於取得。美國、中國和歐洲公司之間的重要合作加速該領域的全球進步。
  • 同種異體TCR-T療法的開發：TCR-T市場的一個重大發展是轉向同種異體TCR-T療法的轉變。這些治療方法使用來自健康捐贈者的T細胞，而非患者自身的T細胞。這種方法有望降低生產成本，並使TCR-T療法更廣泛地普及。開發現成的同種異體TCR-T製劑是一個重要的研究領域，因為它有可能顯著提高治療的擴充性和可負擔性。
  • TCR-T 製造技術的進步：製造技術的進步提高 TCR-T 療法的生產效率和成本效益。包括自動化和細胞培養創新在內的新技術簡化 T 細胞的培養和改造流程。這些進步有望解決當前擴充性的挑戰並降低生產成本，最終使更多患者更容易獲得 TCR-T 療法。

TCR-T 療法市場的最新趨勢，包括 FDA核准、固體癌治療的突破、國際合作、同種異體療法的發展以及製造過程的進步，重塑癌症治療的未來。這些發展推動了 TCR-T 療法的廣泛應用，使其更接近成為全球更多患者的可行治療方案。

目錄

第1章 執行摘要

第2章 市場概況

  • 背景和分類
  • 供應鏈

第3章 市場趨勢及預測分析

  • 產業驅動力與挑戰
  • PESTLE分析
  • 專利分析
  • 法規環境

第4章 全球TCR-T療法市場（依類型）

  • 概述
  • 依類型的吸引力分析
  • 自體移植：趨勢與預測（2019-2031）
  • 同種異體：趨勢與預測（2019-2031）

第5章 全球TCR-T療法市場（依應用）

  • 概述
  • 依用途的吸引力分析
  • 難治性與復發性黑色素瘤：趨勢與預測（2019-2031）
  • 滑膜肉瘤：趨勢與預測（2019-2031）
  • 多發性骨髓瘤：趨勢與預測（2019-2031）
  • 肺癌：趨勢與預測（2019-2031）
  • 其他：趨勢與預測（2019-2031）

第6章 區域分析

  • 概述
  • TCR-T 療法市場（依地區）

第7章 北美TCR-T療法市場

  • 概述
  • 北美TCR-T療法市場（依類型）
  • 北美TCR-T療法市場（依應用）
  • 美國TCR-T療法市場
  • 墨西哥的TCR-T療法市場
  • 加拿大TCR-T療法市場

第8章 歐洲TCR-T療法市場

  • 概述
  • 歐洲TCR-T療法市場（依類型）
  • 歐洲TCR-T療法市場（依應用）
  • 德國TCR-T療法市場
  • 法國TCR-T療法市場
  • 西班牙TCR-T療法市場
  • 義大利TCR-T療法市場
  • 英國TCR-T療法市場

第9章 亞太地區TCR-T療法市場

  • 概述
  • 亞太TCR-T療法市場（依類型）
  • 亞太TCR-T療法市場（依應用）
  • 日本的TCR-T療法市場
  • 印度TCR-T療法市場
  • 中國TCR-T療法市場
  • 韓國TCR-T療法市場
  • 印尼的TCR-T療法市場

第10章 世界其他地區（ROW）TCR-T 療法市場

  • 概述
  • ROW TCR-T 療法市場（依類型）
  • ROW TCR-T 療法市場（依應用）
  • 中東TCR-T療法市場
  • 南美TCR-T療法市場
  • 非洲TCR-T療法市場

第11章 競爭分析

  • 產品系列分析
  • 運作整合
  • 波特五力分析
    • 競爭敵對
    • 買方的議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 新進入者的威脅
  • 市場佔有率分析

第12章 機會與策略分析

  • 價值鏈分析
  • 成長機會分析
    • 依類型分類的成長機會
    • 依應用分類的成長機會
  • 全球TCR-T療法市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 認證和許可
    • 合併、收購、協議、合作和合資企業

第13章 價值鏈主要企業的公司簡介

  • Competitive Analysis
  • Athenex
  • Xiangxue Pharmaceutical（Xiangxue Precision）
  • Hengrui Yuanzheng
  • Eureka Therapeutics
  • Wuxi Juno
  • Shenzhen Inno Immunity
  • Shenzhen Binde Bio

第14章 附錄

  • 圖表目錄
  • 表格列表
  • 調查方法
  • 免責聲明
  • 版權
  • 簡稱和技術單位

The future of the global tcr-t therapy market looks promising with opportunities in the refractory relapsed melanoma, synovial sarcoma, multiple myeloma, lung cancer and other markets. The global tcr-t therapy market is expected to grow with a CAGR of 12.1% from 2025 to 2031. The major drivers for this market are increase in funding for immuno-oncology and rising advancements in genetic engineering techniques.

  • Lucintel forecasts that, within the type category, autologous is expected to witness higher growth over the forecast period.
  • Within the application category, refractory relapsed melanoma is expected to witness the highest growth.
  • In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the TCR-T Therapy Market

The TCR-T therapy market is evolving with emerging trends that are reshaping the landscape of cancer treatment. These trends are largely driven by advancements in technology, personalized medicine, and growing research into immune-based therapies. Below are five key trends that are transforming the TCR-T therapy market.

  • Personalized Cancer Treatment: TCR-T therapy is moving toward a more personalized approach where each patient's unique cancer profile is used to create targeted therapies. This trend involves isolating specific tumor antigens that are unique to a patient's cancer cells and developing T-cells that are engineered to target these antigens. As the precision of TCR-T therapies improves, treatments become more effective, minimizing side effects and increasing the likelihood of successful outcomes.
  • Increased Focus on Solid Tumors: While TCR-T therapy has traditionally been more successful in treating blood cancers, researchers are increasingly focusing on solid tumors. Solid tumors present a more significant challenge due to their complex microenvironments and the difficulty of targeting antigens effectively. However, ongoing innovations in TCR-T technology are making it possible to target solid tumors like lung, breast, and colorectal cancers, significantly expanding the potential applications of TCR-T therapy in cancer treatment.
  • Expansion of Global Clinical Trials: The expansion of clinical trials is another major trend in the TCR-T therapy market. With increased collaboration between biotech firms, academic institutions, and regulatory bodies, clinical trials are growing in number and scope, especially in emerging markets such as China and India. Clinical trials are crucial for demonstrating the safety and efficacy of TCR-T therapies, and as more trials are conducted, the path to approval and widespread adoption becomes clearer.
  • Integration of TCR-T Therapy with Other Immunotherapies: TCR-T therapy is increasingly being combined with other forms of immunotherapy, such as CAR-T therapy, immune checkpoint inhibitors, and cancer vaccines. The goal is to enhance the overall effectiveness of treatment by targeting multiple pathways simultaneously. By combining different immunotherapy approaches, the immune system can be more effectively activated to fight cancer, potentially leading to more durable and long-lasting responses in patients.
  • Advancements in Manufacturing and Scalability: One of the key challenges with TCR-T therapy is the complex and costly process of manufacturing personalized T-cells. However, there are ongoing advancements in the scalability of T-cell production, including the use of automation and artificial intelligence to streamline the process. These advancements are expected to lower the cost of production and make TCR-T therapy more widely available, thereby expanding its reach to a larger patient population.

The TCR-T therapy market is being reshaped by trends like personalized treatment, the focus on solid tumors, global clinical trials, combination therapies, and advancements in manufacturing. These trends promise to improve the accessibility, efficacy, and affordability of TCR-T therapy, bringing it closer to becoming a mainstream cancer treatment option.

Recent Developments in the TCR-T Therapy Market

The TCR-T therapy market is experiencing rapid growth, driven by advancements in research, clinical trials, and regulatory approvals. In recent years, significant developments have been made in enhancing the effectiveness and accessibility of TCR-T therapies. Below are five key developments that have shaped the current landscape of the TCR-T therapy market.

  • FDA Approval of TCR-T Therapies: The U.S. Food and Drug Administration (FDA) has recently approved several TCR-T therapies for use in treating blood cancers like melanoma and leukemia. These approvals mark a critical step forward in the commercialization of TCR-T therapy, providing patients with access to cutting-edge treatments. The FDA's approval process for TCR-T therapies has been accelerated, particularly for life-threatening cancers, reflecting the growing recognition of the technology's potential.
  • Breakthroughs in Solid Tumor Treatment: Significant progress has been made in adapting TCR-T therapies for solid tumors. Historically, TCR-T therapies have been more effective for treating hematological cancers, but new strategies are emerging to overcome the challenges posed by solid tumors. Clinical trials focusing on cancers like lung, colorectal, and pancreatic are showing promising results, which could vastly expand the market for TCR-T therapy and make it an option for a broader patient base.
  • International Collaborations for TCR-T Development: International partnerships are becoming increasingly common in the development of TCR-T therapies. Collaboration between biotech firms, academic institutions, and healthcare providers is helping to streamline the clinical trial process and share knowledge and resources. These partnerships are also helping to reduce the cost of TCR-T development, making the therapy more affordable and accessible. Key collaborations between companies in the U.S., China, and Europe are accelerating global progress in the field.
  • Development of Allogeneic TCR-T Therapies: A major development in the TCR-T market is the movement toward allogeneic TCR-T therapies. These therapies use T-cells from healthy donors rather than the patient's own T-cells. This approach has the potential to reduce manufacturing costs and make TCR-T therapy more widely available. The development of off-the-shelf allogeneic TCR-T products is an area of significant research, as it could drastically improve the scalability and affordability of the therapy.
  • Advances in TCR-T Manufacturing Technologies: Advancements in manufacturing technologies are improving the efficiency and cost-effectiveness of TCR-T therapy production. New techniques, including automation and cell-culture innovations, are streamlining the process of growing and modifying T-cells. These advances are expected to address the current challenges of scalability and reduce the cost of production, ultimately making TCR-T therapies more accessible to a larger patient population.

Recent developments in the TCR-T therapy market, such as FDA approvals, breakthroughs in solid tumor treatment, international collaborations, the development of allogeneic therapies, and advancements in manufacturing, are reshaping the future of cancer treatment. These developments are helping to drive the widespread adoption of TCR-T therapy, bringing it closer to becoming a viable option for more patients worldwide.

Strategic Growth Opportunities in the TCR-T Therapy Market

The TCR-T therapy market is expected to grow substantially in the coming years, with several strategic growth opportunities emerging across key applications. These opportunities are driven by advancements in research, regulatory support, and the increasing demand for personalized cancer treatments. Below are five key growth opportunities in the TCR-T therapy market.

  • Expansion of TCR-T Applications in Oncology: The primary application for TCR-T therapy is in oncology, where it is increasingly being used to treat a range of cancers, including both hematological and solid tumors. There is substantial growth potential in expanding TCR-T therapy applications across different cancer types, particularly in solid tumors. As research continues to progress, more types of cancer will be targeted, providing a broader market opportunity for TCR-T therapies.
  • Global Market Penetration: With the increasing global recognition of TCR-T therapy's potential, there is significant growth potential in expanding its availability worldwide. Emerging markets, including China, India, and Latin America, present untapped opportunities. Regulatory approvals, clinical trials, and strategic partnerships will be key to accessing these markets and making TCR-T therapies available to a larger patient population.
  • Combination Therapies with Other Immunotherapies: Combining TCR-T therapy with other immunotherapies, such as CAR-T therapy, immune checkpoint inhibitors, and cancer vaccines, presents a growth opportunity. This combination approach has the potential to enhance the effectiveness of treatment and provide more durable responses in patients. As new combination therapies are developed, the market for TCR-T therapy will expand.
  • Adoption in Personalized Medicine: As the shift toward personalized medicine continues, TCR-T therapy stands to benefit from being at the forefront of this movement. Personalized cancer treatments that are tailored to an individual's genetic profile will enhance the effectiveness of TCR-T therapies. By focusing on patient-specific antigens and cancer profiles, TCR-T therapies will become more customized, which is expected to improve patient outcomes and expand the market.
  • Investment in Manufacturing Innovations: The development of scalable and cost-effective manufacturing solutions is critical for the growth of TCR-T therapy. Advances in biomanufacturing, automation, and cell-culture technologies are reducing production costs and increasing efficiency. Investment in manufacturing innovations will make TCR-T therapies more widely available, lowering costs and improving market accessibility.

Strategic growth opportunities in the TCR-T therapy market, including expansion into new oncology applications, global market penetration, combination therapies, personalized medicine, and manufacturing innovations, are expected to drive market growth. These opportunities will make TCR-T therapies more accessible and effective, paving the way for their widespread use in cancer treatment.

TCR-T Therapy Market Driver and Challenges

The TCR-T therapy market is influenced by several key drivers and challenges, ranging from technological advancements to regulatory factors. Understanding these factors is crucial for stakeholders looking to capitalize on the growth of the market. Below are five major drivers and three key challenges impacting the TCR-T therapy market.

The factors responsible for driving the TCR-T Therapy market include:

1. Technological Advancements in Gene Editing: Advancements in gene-editing technologies, such as CRISPR, are a major driver of the TCR-T therapy market. These technologies allow for precise modifications of T-cells, improving the efficacy of TCR-T therapies. As gene-editing techniques become more refined, the potential applications of TCR-T therapy will expand, allowing for more targeted treatments with fewer side effects.

2. Increased Investment in Cancer Immunotherapy: The growing recognition of immunotherapy's potential is driving investment in TCR-T therapy. Funding from both public and private sectors is increasing, leading to more research and development. This financial support is accelerating the progress of TCR-T therapy, resulting in faster clinical trials and the development of more effective treatments.

3. Regulatory Support for Immunotherapies: Regulatory bodies, such as the FDA and EMA, are providing increasing support for the development and approval of TCR-T therapies. This support includes fast-tracking the approval process for promising therapies and providing funding for clinical trials. Regulatory incentives are accelerating the availability of TCR-T therapies, allowing for quicker commercialization.

4. Growing Demand for Personalized Medicine: Personalized medicine is becoming a cornerstone of modern healthcare, and TCR-T therapy is at the forefront of this movement. As the demand for treatments tailored to individual patients' genetic profiles grows, TCR-T therapy is positioned to play a major role in cancer treatment. The shift toward precision medicine is a key driver for the TCR-T therapy market.

5. Rising Cancer Incidence: The increasing incidence of cancer worldwide is another driver for the TCR-T therapy market. As the global cancer burden grows, the demand for innovative treatments, including TCR-T therapies, increases. This trend is expected to continue as the global population ages and lifestyle factors contribute to higher cancer rates.

Challenges in the TCR-T Therapy market are:

1. High Manufacturing Costs: One of the major challenges with TCR-T therapy is the high cost of manufacturing. The complex process of isolating and modifying T-cells is resource-intensive, making the therapy expensive. As a result, the therapy is not yet widely accessible to all patients. Reducing manufacturing costs is critical for the future scalability of TCR-T therapy.

2. Limited Efficacy in Solid Tumors: While TCR-T therapy has shown promising results in treating blood cancers, its efficacy in solid tumors remains a challenge. Solid tumors have complex microenvironments that can inhibit the effectiveness of TCR-T therapies. Overcoming this challenge is a key area of research that could significantly expand the market.

3. Regulatory Hurdles: Although regulatory support for TCR-T therapy is increasing, the approval process for new therapies is still lengthy and complex. Navigating the regulatory landscape can delay the time-to-market for new treatments. Furthermore, inconsistent regulatory standards across different regions can create barriers to the global adoption of TCR-T therapies.

The TCR-T therapy market is driven by technological advancements, investment in immunotherapy, regulatory support, demand for personalized medicine, and the rising incidence of cancer. However, challenges such as high manufacturing costs, limited efficacy in solid tumors, and regulatory hurdles need to be addressed for the market to reach its full potential. By overcoming these challenges, TCR-T therapy has the potential to revolutionize cancer treatment.

List of TCR-T Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies tcr-t therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the tcr-t therapy companies profiled in this report include-

  • Athenex
  • Xiangxue Pharmaceutical (Xiangxue Precision)
  • Hengrui Yuanzheng
  • Eureka Therapeutics
  • Wuxi Juno
  • Shenzhen Inno Immunity
  • Shenzhen Binde Bio

TCR-T Therapy Market by Segment

The study includes a forecast for the global tcr-t therapy market by type, application, and region.

TCR-T Therapy Market by Type [Value from 2019 to 2031]:

  • Autologous
  • Allogeneic

TCR-T Therapy Market by Application [Value from 2019 to 2031]:

  • Refractory Relapsed Melanoma
  • Synovial Sarcoma
  • Multiple Myeloma
  • Lung Cancer
  • Others

TCR-T Therapy Market by Region [Value from 2019 to 2031]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the TCR-T Therapy Market

TCR-T (T-cell receptor-engineered T-cell) therapy is a promising cancer treatment that is revolutionizing immunotherapy. It involves modifying a patient's own T-cells to recognize and target cancer cells more effectively. With advancements in genetic engineering, enhanced understanding of tumor antigens, and breakthroughs in clinical trials, TCR-T therapy is gaining traction worldwide. In countries like the United States, China, Germany, India, and Japan, the TCR-T therapy market is evolving rapidly, driven by both scientific innovation and increasing demand for personalized medicine. Below are some of the key recent developments in the TCR-T therapy market in these countries.

  • United States: In the United States, TCR-T therapy is witnessing significant progress, particularly in the oncology sector. Several biotech companies and academic institutions are leading the charge, with many ongoing clinical trials targeting solid tumors and hematological cancers. Key advancements include the development of next-generation TCR-T therapies that are more effective at targeting specific tumor antigens. The U.S. Food and Drug Administration (FDA) has accelerated the approval process for certain TCR-T therapies, facilitating market access. Furthermore, partnerships between biotech firms and pharmaceutical companies are pushing the therapy closer to commercialization, making it a central area of focus for cancer treatment innovation.
  • China: China is investing heavily in the development of TCR-T therapies, and the market has seen substantial growth in the past few years. Chinese biotech companies are conducting clinical trials in collaboration with international partners to develop TCR-T therapies for various cancers, including lung cancer and liver cancer. The Chinese government has also been supportive of cancer immunotherapy research through favorable policies and funding. One notable development is the approval of a few TCR-T therapies for certain blood cancers. Additionally, the scale-up of cell manufacturing facilities is increasing, which is expected to enhance the availability of TCR-T therapies at a larger scale in China
  • Germany: Germany is a hub for research and innovation in TCR-T therapy, with several academic and research institutes focusing on advancing this technology. German biotech companies are actively involved in clinical trials, particularly for the treatment of melanoma, glioblastoma, and other solid tumors. The German regulatory environment is also becoming more conducive to the adoption of TCR-T therapy, with the European Medicines Agency (EMA) working on faster approvals for promising therapies. Germany is also seeing an increase in public-private collaborations to accelerate the development of TCR-T therapies, which is contributing to a more robust clinical and regulatory framework for these treatments
  • India: In India, TCR-T therapy is in the early stages of development, but the market is witnessing growing interest from both researchers and patients. The Indian government is investing in medical research, and various private and public institutions are collaborating on clinical trials of TCR-T therapies for cancer treatment. Additionally, India's large patient pool provides an opportunity for conducting clinical trials at a lower cost, making it an attractive destination for international biotech companies. While the technology is still in its nascent stages, India's regulatory body, the Central Drugs Standard Control Organization (CDSCO), is gradually opening up to innovations in immunotherapy.
  • Japan: Japan is one of the leading countries in adopting and advancing TCR-T therapy, particularly in the oncology field. Japanese biotech companies are focusing on TCR-T therapies for cancers such as colorectal cancer, lung cancer, and leukemia. In 2022, Japan's Ministry of Health, Labour, and Welfare (MHLW) approved the first TCR-T therapy for clinical use, which marked a significant milestone. The Japanese government has implemented supportive policies to accelerate the development of immunotherapies, and public-private partnerships are becoming increasingly common. Furthermore, Japan's advanced healthcare infrastructure and patient-focused treatment options make it an attractive market for TCR-T therapy.

Features of the Global TCR-T Therapy Market

  • Market Size Estimates: Tcr-t therapy market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
  • Segmentation Analysis: Tcr-t therapy market size by type, application, and region in terms of value ($B).
  • Regional Analysis: Tcr-t therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the tcr-t therapy market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the tcr-t therapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the tcr-t therapy market by type (autologous and allogeneic), application (refractory relapsed melanoma, synovial sarcoma, multiple myeloma, lung cancer, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global TCR-T Therapy Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 Autologous: Trends and Forecast (2019-2031)
  • 4.4 Allogeneic: Trends and Forecast (2019-2031)

5. Global TCR-T Therapy Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 Refractory Relapsed Melanoma: Trends and Forecast (2019-2031)
  • 5.4 Synovial Sarcoma: Trends and Forecast (2019-2031)
  • 5.5 Multiple Myeloma: Trends and Forecast (2019-2031)
  • 5.6 Lung Cancer: Trends and Forecast (2019-2031)
  • 5.7 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global TCR-T Therapy Market by Region

7. North American TCR-T Therapy Market

  • 7.1 Overview
  • 7.2 North American TCR-T Therapy Market by type
  • 7.3 North American TCR-T Therapy Market by application
  • 7.4 United States TCR-T Therapy Market
  • 7.5 Mexican TCR-T Therapy Market
  • 7.6 Canadian TCR-T Therapy Market

8. European TCR-T Therapy Market

  • 8.1 Overview
  • 8.2 European TCR-T Therapy Market by type
  • 8.3 European TCR-T Therapy Market by application
  • 8.4 German TCR-T Therapy Market
  • 8.5 French TCR-T Therapy Market
  • 8.6 Spanish TCR-T Therapy Market
  • 8.7 Italian TCR-T Therapy Market
  • 8.8 United Kingdom TCR-T Therapy Market

9. APAC TCR-T Therapy Market

  • 9.1 Overview
  • 9.2 APAC TCR-T Therapy Market by type
  • 9.3 APAC TCR-T Therapy Market by application
  • 9.4 Japanese TCR-T Therapy Market
  • 9.5 Indian TCR-T Therapy Market
  • 9.6 Chinese TCR-T Therapy Market
  • 9.7 South Korean TCR-T Therapy Market
  • 9.8 Indonesian TCR-T Therapy Market

10. ROW TCR-T Therapy Market

  • 10.1 Overview
  • 10.2 ROW TCR-T Therapy Market by type
  • 10.3 ROW TCR-T Therapy Market by application
  • 10.4 Middle Eastern TCR-T Therapy Market
  • 10.5 South American TCR-T Therapy Market
  • 10.6 African TCR-T Therapy Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunities by Type
    • 12.2.2 Growth Opportunities by Application
  • 12.3 Emerging Trends in the Global TCR-T Therapy Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis
  • 13.2 Athenex
    • Company Overview
    • TCR-T Therapy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 Xiangxue Pharmaceutical (Xiangxue Precision)
    • Company Overview
    • TCR-T Therapy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Hengrui Yuanzheng
    • Company Overview
    • TCR-T Therapy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 Eureka Therapeutics
    • Company Overview
    • TCR-T Therapy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 Wuxi Juno
    • Company Overview
    • TCR-T Therapy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.7 Shenzhen Inno Immunity
    • Company Overview
    • TCR-T Therapy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.8 Shenzhen Binde Bio
    • Company Overview
    • TCR-T Therapy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global TCR-T Therapy Market
  • Figure 2.1: Usage of TCR-T Therapy Market
  • Figure 2.2: Classification of the Global TCR-T Therapy Market
  • Figure 2.3: Supply Chain of the Global TCR-T Therapy Market
  • Figure 3.1: Driver and Challenges of the TCR-T Therapy Market
  • Figure 3.2: PESTLE Analysis
  • Figure 3.3: Patent Analysis
  • Figure 3.4: Regulatory Environment
  • Figure 4.1: Global TCR-T Therapy Market by Type in 2019, 2024, and 2031
  • Figure 4.2: Trends of the Global TCR-T Therapy Market ($B) by Type
  • Figure 4.3: Forecast for the Global TCR-T Therapy Market ($B) by Type
  • Figure 4.4: Trends and Forecast for Autologous in the Global TCR-T Therapy Market (2019-2031)
  • Figure 4.5: Trends and Forecast for Allogeneic in the Global TCR-T Therapy Market (2019-2031)
  • Figure 5.1: Global TCR-T Therapy Market by Application in 2019, 2024, and 2031
  • Figure 5.2: Trends of the Global TCR-T Therapy Market ($B) by Application
  • Figure 5.3: Forecast for the Global TCR-T Therapy Market ($B) by Application
  • Figure 5.4: Trends and Forecast for Refractory Relapsed Melanoma in the Global TCR-T Therapy Market (2019-2031)
  • Figure 5.5: Trends and Forecast for Synovial Sarcoma in the Global TCR-T Therapy Market (2019-2031)
  • Figure 5.6: Trends and Forecast for Multiple Myeloma in the Global TCR-T Therapy Market (2019-2031)
  • Figure 5.7: Trends and Forecast for Lung Cancer in the Global TCR-T Therapy Market (2019-2031)
  • Figure 5.8: Trends and Forecast for Others in the Global TCR-T Therapy Market (2019-2031)
  • Figure 6.1: Trends of the Global TCR-T Therapy Market ($B) by Region (2019-2024)
  • Figure 6.2: Forecast for the Global TCR-T Therapy Market ($B) by Region (2025-2031)
  • Figure 7.1: North American TCR-T Therapy Market by type in 2019, 2024, and 2031
  • Figure 7.2: Trends of the North American TCR-T Therapy Market ($B) by type (2019-2024)
  • Figure 7.3: Forecast for the North American TCR-T Therapy Market ($B) by type (2025-2031)
  • Figure 7.4: North American TCR-T Therapy Market by application in 2019, 2024, and 2031
  • Figure 7.5: Trends of the North American TCR-T Therapy Market ($B) by application (2019-2024)
  • Figure 7.6: Forecast for the North American TCR-T Therapy Market ($B) by application (2025-2031)
  • Figure 7.7: Trends and Forecast for the United States TCR-T Therapy Market ($B) (2019-2031)
  • Figure 7.8: Trends and Forecast for the Mexican TCR-T Therapy Market ($B) (2019-2031)
  • Figure 7.9: Trends and Forecast for the Canadian TCR-T Therapy Market ($B) (2019-2031)
  • Figure 8.1: European TCR-T Therapy Market by type in 2019, 2024, and 2031
  • Figure 8.2: Trends of the European TCR-T Therapy Market ($B) by type (2019-2024)
  • Figure 8.3: Forecast for the European TCR-T Therapy Market ($B) by type (2025-2031)
  • Figure 8.4: European TCR-T Therapy Market by application in 2019, 2024, and 2031
  • Figure 8.5: Trends of the European TCR-T Therapy Market ($B) by application (2019-2024)
  • Figure 8.6: Forecast for the European TCR-T Therapy Market ($B) by application (2025-2031)
  • Figure 8.7: Trends and Forecast for the German TCR-T Therapy Market ($B) (2019-2031)
  • Figure 8.8: Trends and Forecast for the French TCR-T Therapy Market ($B) (2019-2031)
  • Figure 8.9: Trends and Forecast for the Spanish TCR-T Therapy Market ($B) (2019-2031)
  • Figure 8.10: Trends and Forecast for the Italian TCR-T Therapy Market ($B) (2019-2031)
  • Figure 8.11: Trends and Forecast for the United Kingdom TCR-T Therapy Market ($B) (2019-2031)
  • Figure 9.1: APAC TCR-T Therapy Market by type in 2019, 2024, and 2031
  • Figure 9.2: Trends of the APAC TCR-T Therapy Market ($B) by type (2019-2024)
  • Figure 9.3: Forecast for the APAC TCR-T Therapy Market ($B) by type (2025-2031)
  • Figure 9.4: APAC TCR-T Therapy Market by application in 2019, 2024, and 2031
  • Figure 9.5: Trends of the APAC TCR-T Therapy Market ($B) by application (2019-2024)
  • Figure 9.6: Forecast for the APAC TCR-T Therapy Market ($B) by application (2025-2031)
  • Figure 9.7: Trends and Forecast for the Japanese TCR-T Therapy Market ($B) (2019-2031)
  • Figure 9.8: Trends and Forecast for the Indian TCR-T Therapy Market ($B) (2019-2031)
  • Figure 9.9: Trends and Forecast for the Chinese TCR-T Therapy Market ($B) (2019-2031)
  • Figure 9.10: Trends and Forecast for the South Korean TCR-T Therapy Market ($B) (2019-2031)
  • Figure 9.11: Trends and Forecast for the Indonesian TCR-T Therapy Market ($B) (2019-2031)
  • Figure 10.1: ROW TCR-T Therapy Market by type in 2019, 2024, and 2031
  • Figure 10.2: Trends of the ROW TCR-T Therapy Market ($B) by type (2019-2024)
  • Figure 10.3: Forecast for the ROW TCR-T Therapy Market ($B) by type (2025-2031)
  • Figure 10.4: ROW TCR-T Therapy Market by application in 2019, 2024, and 2031
  • Figure 10.5: Trends of the ROW TCR-T Therapy Market ($B) by application (2019-2024)
  • Figure 10.6: Forecast for the ROW TCR-T Therapy Market ($B) by application (2025-2031)
  • Figure 10.7: Trends and Forecast for the Middle Eastern TCR-T Therapy Market ($B) (2019-2031)
  • Figure 10.8: Trends and Forecast for the South American TCR-T Therapy Market ($B) (2019-2031)
  • Figure 10.9: Trends and Forecast for the African TCR-T Therapy Market ($B) (2019-2031)
  • Figure 11.1: Porter's Five Forces Analysis of the Global TCR-T Therapy Market
  • Figure 11.2: Market Share (%) of Top Players in the Global TCR-T Therapy Market (2024)
  • Figure 12.1: Growth Opportunities for the Global TCR-T Therapy Market by Type
  • Figure 12.2: Growth Opportunities for the Global TCR-T Therapy Market by Application
  • Figure 12.3: Growth Opportunities for the Global TCR-T Therapy Market by Region
  • Figure 12.4: Emerging Trends in the Global TCR-T Therapy Market

List of Tables

  • Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the TCR-T Therapy Market by Type and Application
  • Table 1.2: Attractiveness Analysis for the TCR-T Therapy Market by Region
  • Table 1.3: Global TCR-T Therapy Market Parameters and Attributes
  • Table 3.1: Trends of the Global TCR-T Therapy Market (2019-2024)
  • Table 3.2: Forecast for the Global TCR-T Therapy Market (2025-2031)
  • Table 4.1: Attractiveness Analysis for the Global TCR-T Therapy Market by Type
  • Table 4.2: Market Size and CAGR of Various Type in the Global TCR-T Therapy Market (2019-2024)
  • Table 4.3: Market Size and CAGR of Various Type in the Global TCR-T Therapy Market (2025-2031)
  • Table 4.4: Trends of Autologous in the Global TCR-T Therapy Market (2019-2024)
  • Table 4.5: Forecast for Autologous in the Global TCR-T Therapy Market (2025-2031)
  • Table 4.6: Trends of Allogeneic in the Global TCR-T Therapy Market (2019-2024)
  • Table 4.7: Forecast for Allogeneic in the Global TCR-T Therapy Market (2025-2031)
  • Table 5.1: Attractiveness Analysis for the Global TCR-T Therapy Market by Application
  • Table 5.2: Market Size and CAGR of Various Application in the Global TCR-T Therapy Market (2019-2024)
  • Table 5.3: Market Size and CAGR of Various Application in the Global TCR-T Therapy Market (2025-2031)
  • Table 5.4: Trends of Refractory Relapsed Melanoma in the Global TCR-T Therapy Market (2019-2024)
  • Table 5.5: Forecast for Refractory Relapsed Melanoma in the Global TCR-T Therapy Market (2025-2031)
  • Table 5.6: Trends of Synovial Sarcoma in the Global TCR-T Therapy Market (2019-2024)
  • Table 5.7: Forecast for Synovial Sarcoma in the Global TCR-T Therapy Market (2025-2031)
  • Table 5.8: Trends of Multiple Myeloma in the Global TCR-T Therapy Market (2019-2024)
  • Table 5.9: Forecast for Multiple Myeloma in the Global TCR-T Therapy Market (2025-2031)
  • Table 5.10: Trends of Lung Cancer in the Global TCR-T Therapy Market (2019-2024)
  • Table 5.11: Forecast for Lung Cancer in the Global TCR-T Therapy Market (2025-2031)
  • Table 5.12: Trends of Others in the Global TCR-T Therapy Market (2019-2024)
  • Table 5.13: Forecast for Others in the Global TCR-T Therapy Market (2025-2031)
  • Table 6.1: Market Size and CAGR of Various Regions in the Global TCR-T Therapy Market (2019-2024)
  • Table 6.2: Market Size and CAGR of Various Regions in the Global TCR-T Therapy Market (2025-2031)
  • Table 7.1: Trends of the North American TCR-T Therapy Market (2019-2024)
  • Table 7.2: Forecast for the North American TCR-T Therapy Market (2025-2031)
  • Table 7.3: Market Size and CAGR of Various type in the North American TCR-T Therapy Market (2019-2024)
  • Table 7.4: Market Size and CAGR of Various type in the North American TCR-T Therapy Market (2025-2031)
  • Table 7.5: Market Size and CAGR of Various application in the North American TCR-T Therapy Market (2019-2024)
  • Table 7.6: Market Size and CAGR of Various application in the North American TCR-T Therapy Market (2025-2031)
  • Table 7.7: Trends and Forecast for the United States TCR-T Therapy Market (2019-2031)
  • Table 7.8: Trends and Forecast for the Mexican TCR-T Therapy Market (2019-2031)
  • Table 7.9: Trends and Forecast for the Canadian TCR-T Therapy Market (2019-2031)
  • Table 8.1: Trends of the European TCR-T Therapy Market (2019-2024)
  • Table 8.2: Forecast for the European TCR-T Therapy Market (2025-2031)
  • Table 8.3: Market Size and CAGR of Various type in the European TCR-T Therapy Market (2019-2024)
  • Table 8.4: Market Size and CAGR of Various type in the European TCR-T Therapy Market (2025-2031)
  • Table 8.5: Market Size and CAGR of Various application in the European TCR-T Therapy Market (2019-2024)
  • Table 8.6: Market Size and CAGR of Various application in the European TCR-T Therapy Market (2025-2031)
  • Table 8.7: Trends and Forecast for the German TCR-T Therapy Market (2019-2031)
  • Table 8.8: Trends and Forecast for the French TCR-T Therapy Market (2019-2031)
  • Table 8.9: Trends and Forecast for the Spanish TCR-T Therapy Market (2019-2031)
  • Table 8.10: Trends and Forecast for the Italian TCR-T Therapy Market (2019-2031)
  • Table 8.11: Trends and Forecast for the United Kingdom TCR-T Therapy Market (2019-2031)
  • Table 9.1: Trends of the APAC TCR-T Therapy Market (2019-2024)
  • Table 9.2: Forecast for the APAC TCR-T Therapy Market (2025-2031)
  • Table 9.3: Market Size and CAGR of Various type in the APAC TCR-T Therapy Market (2019-2024)
  • Table 9.4: Market Size and CAGR of Various type in the APAC TCR-T Therapy Market (2025-2031)
  • Table 9.5: Market Size and CAGR of Various application in the APAC TCR-T Therapy Market (2019-2024)
  • Table 9.6: Market Size and CAGR of Various application in the APAC TCR-T Therapy Market (2025-2031)
  • Table 9.7: Trends and Forecast for the Japanese TCR-T Therapy Market (2019-2031)
  • Table 9.8: Trends and Forecast for the Indian TCR-T Therapy Market (2019-2031)
  • Table 9.9: Trends and Forecast for the Chinese TCR-T Therapy Market (2019-2031)
  • Table 9.10: Trends and Forecast for the South Korean TCR-T Therapy Market (2019-2031)
  • Table 9.11: Trends and Forecast for the Indonesian TCR-T Therapy Market (2019-2031)
  • Table 10.1: Trends of the ROW TCR-T Therapy Market (2019-2024)
  • Table 10.2: Forecast for the ROW TCR-T Therapy Market (2025-2031)
  • Table 10.3: Market Size and CAGR of Various type in the ROW TCR-T Therapy Market (2019-2024)
  • Table 10.4: Market Size and CAGR of Various type in the ROW TCR-T Therapy Market (2025-2031)
  • Table 10.5: Market Size and CAGR of Various application in the ROW TCR-T Therapy Market (2019-2024)
  • Table 10.6: Market Size and CAGR of Various application in the ROW TCR-T Therapy Market (2025-2031)
  • Table 10.7: Trends and Forecast for the Middle Eastern TCR-T Therapy Market (2019-2031)
  • Table 10.8: Trends and Forecast for the South American TCR-T Therapy Market (2019-2031)
  • Table 10.9: Trends and Forecast for the African TCR-T Therapy Market (2019-2031)
  • Table 11.1: Product Mapping of TCR-T Therapy Suppliers Based on Segments
  • Table 11.2: Operational Integration of TCR-T Therapy Manufacturers
  • Table 11.3: Rankings of Suppliers Based on TCR-T Therapy Revenue
  • Table 12.1: New Product Launches by Major TCR-T Therapy Producers (2019-2024)
  • Table 12.2: Certification Acquired by Major Competitor in the Global TCR-T Therapy Market